Inferra AI / Company / AXGN

Axogen, Inc.

AXGN · Health Care

Last earnings Oct 28, 2026

Key results

Revenuequarter

$60.1 million

Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a 6.0% increase over the second quarter of 2025.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Gross marginquarter

76.6%

For the third quarter of 2025, gross margin was 76.6%, up from 74.9% for the third quarter of 2024, and up from 74.2% in the second quarter of 2025.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Net incomequarter

$0.7 million

Net income for the quarter was $0.7 million, or $0.01 per share, compared to a Net loss of $1.9 million, or $0.04 per share for the third quarter of 2024.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Adjusted net incomequarter

$6.1 million

Adjusted net income for the quarter was $6.1 million, or $0.12 per share, compared to $3.1 million, or $0.07 per share, for the third quarter of 2024.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Our third quarter performance reflects the continued maturation of the peripheral nerve repair market, with revenue growing 23.5% to $60.1 million and adjusted EBITDA of $9.2 million as we scale our commercial operations, commented Michael Dale, CEO and Director of Axogen, Inc.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

revenue increased to $60.1M, growing 23.5% YoY Q3 reflected broad-based growth across the entire portfolio Double-digit growth performance in all markets High Potential Accounts YTD, HiPo accounts yielded approx.

SEC original ↗Axogen, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2025

YoY revenueytd

66%

64% of YoY revenue growth (vs 2025 66% goal) YTD, HiPo accounts have yielded 19% YoY increase in average account productivity (vs 2025 21% goal) 668 Active HiPo accounts in the first three quarters of 2025; an increase of 1.2% YoY Professional Education Breast: ended Q3 with 22 specialists and 2 regional sales directors ("RSD") Extremities: ended Q3 with 110 reps and 15 RSDs OMF/H&N: ended Q3 with 4 market development managers Commercial Infrastructure Breast: 62 surgeon pairs trained YTD (vs.

SEC original ↗Axogen, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2025

Gross margin of 73% - 75% Net cash flow positive* 13 * Net change in cash, cash equivalents, restricted cash, and investments.

SEC original ↗Axogen, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2025

Research and developmentquarter

$7,565 thousand

Research and development 7,565 6,996 20,509 21,063

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

AI analysis

Q3 2025 · reported Oct 29, 2025

Based on: Earnings release + Q3 2025 deck + parent 8-K — transcript not held

Revenue · Q3 2025

$60.1M

EX-99 · Oct 29, 2025

Gross margin · Q3 2025

76.6%

+1.7 pts vs year ago computed from stated figures

EX-99 · Oct 29, 2025

Net income · Q3 2025

$0.7M

EX-99 · Oct 29, 2025

Adjusted net income · Q3 2025

$6.1M

EX-99 · Oct 29, 2025

The quarter in charts

GAAP gross margin

Percent of revenue, as stated

EX-99 · Oct 29, 2025 Margin values as stated in the release.

Guidance ladder — revenue

Delivered vs the company's guided range

Q3 2025 delivered$60.1M

Guided range (company-stated)$0.2B · midpoint $0.2B

0$B

EX-99 · Oct 29, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

Metric	Q3 2025	Prior qtr	Year ago
Revenue	$60.1 million	—	—
Gross margin	76.6%	—	74.9%
Net income	$0.7 million	—	—
Adjusted net income	$6.1 million	—	—
Research and development	$7,565 thousand	—	—

EX-99 · Oct 29, 2025

Guidance · company-stated

Direction: Raised

Revenue$222.8 million

“Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA and TAMPA, FL October 29, 2025 Axogen, Inc.”

Revenue

“2025 Financial Guidance We are raising our revenue guidance to at least 19% growth, or $222.8 million for the full year.”

Midpoint vs latest-quarter revenue+270.7%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Gross margin76.6%

Capital allocation

We also use the Operational Cashflow metric, which corresponds to Net change in cash, cash equivalents, restricted cash, and investments, less cashflow from issuance or repayment of long-term debt.

We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business, the Company s cash available for operations, and the Company s ability to meet future capital expenditure and working capital requirements.

What changed vs last quarter

Guide midpoint vs latest-quarter revenue +270.7% computed from stated figures

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA and TAMPA, FL October 29, 2025

Based on: Earnings release + Q3 2025 deck + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA and TAMPA, FL October 29, 2025 Axogen, Inc.”

Revenue: “2025 Financial Guidance We are raising our revenue guidance to at least 19% growth, or $222.8 million for the full year.”

Revenue — Raised (“Raises”)
“Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA and TAMPA, FL October 29, 2025 Axogen, Inc.”

Revenue — Raised (“raising”)
“2025 Financial Guidance We are raising our revenue guidance to at least 19% growth, or $222.8 million for the full year.”

Classified from the release's primary full-year outlook statement.

Capital allocation

We also use the Operational Cashflow metric, which corresponds to Net change in cash, cash equivalents, restricted cash, and investments, less cashflow from issuance or repayment of long-term debt.

SEC original ↗Axogen, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2025

Strategy & priorities

New position statements from AAHS and ASRM, together with AAOMS guidelines recognizing nerve allografts as standard medical practice, and the addition of 1.1 million additional covered lives, validate our ongoing market development strategy.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Words such as expects, anticipates, priorities, objectives, targets, intends, plan(s), believes, seeks, estimates, projects, forecasts, continue, may, should, will, goals, and variations of such words and similar expressions are intended to identify such forward-looking statements.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Words such as expects, anticipates, priorities, objectives, intends, plans, believes, seeks, estimates, projects, forecasts, continue, may, should, will, goals, and variations of such words and similar expressions are intended to identify such forward-looking statements.

SEC original ↗Axogen, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2025

OMF/H&N clinical evidence plan Innovation Therapeutic reconstruction Ease of coaptation Protection expansion Prostate Clinical & Market Development AAHS and ASRM recognizes Avance® Nerve Graft as standard medical practice in Q3 339 peer-reviewed articles, +10 in Q3 ~1.1M est.

SEC original ↗Axogen, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 29, 2025

Risks & headwinds

, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2024 and other risks and uncertainties, which may be detailed from time to time in reports filed by the Company with the SEC.

SEC original ↗Axogen, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2025

Documents

Earnings deck slides

0 decks with slide view

Axogen, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors